5138 GENES FOUND
Show / hide columns »
XML |
RDF |
TAB |
« prev | Page next »
KCNB2 Potassium channel, voltage gated Shab related subfamily B, member 2 FDA approved drug targets Nucleoli Tissue enhanced
KCNC1 Potassium channel, voltage gated Shaw related subfamily C, member 1 Disease related genes Nucleus Tissue enriched
KCNC2 Potassium channel, voltage gated Shaw related subfamily C, member 2 FDA approved drug targets Plasma membrane Tissue enriched
KCNC3 Potassium channel, voltage gated Shaw related subfamily C, member 3 Disease related genes Tissue enhanced
KCNC4 Potassium channel, voltage gated Shaw related subfamily C, member 4 Predicted membrane proteins Nucleoli Mixed
KCND1 Potassium channel, voltage gated Shal related subfamily D, member 1 FDA approved drug targets Nucleus Mixed
KCND2 Potassium channel, voltage gated Shal related subfamily D, member 2 Disease related genes Tissue enhanced
KCND3 Potassium channel, voltage gated Shal related subfamily D, member 3 Disease related genes Mixed
KCNE2 Potassium channel, voltage gated subfamily E regulatory beta subunit 2 Disease related genes Tissue enriched
KCNE3 Potassium channel, voltage gated subfamily E regulatory beta subunit 3 Predicted intracellular proteins Mixed
KCNE4 Potassium channel, voltage gated subfamily E regulatory beta subunit 4 Predicted membrane proteins Nuclear bodies Tissue enhanced
KCNE5 Potassium channel, voltage gated subfamily E regulatory beta subunit 5 Disease related genes Cytosol Tissue enhanced
KCNF1 Potassium channel, voltage gated modifier subfamily F, member 1 Plasma proteins Golgi apparatus Tissue enriched
KCNG1 Potassium channel, voltage gated modifier subfamily G, member 1 Predicted intracellular proteins Vesicles Tissue enhanced
KCNG2 Potassium channel, voltage gated modifier subfamily G, member 2 Predicted membrane proteins Not detected
KCNG3 Potassium channel, voltage gated modifier subfamily G, member 3 Predicted membrane proteins Cytoplasmic bodies Tissue enhanced
KCNG4 Potassium channel, voltage gated modifier subfamily G, member 4 Predicted membrane proteins Not detected
KCNH1 Potassium channel, voltage gated eag related subfamily H, member 1 Disease related genes Vesicles Tissue enriched
KCNH3 Potassium channel, voltage gated eag related subfamily H, member 3 Predicted membrane proteins Nucleus Group enriched
KCNH5 Potassium channel, voltage gated eag related subfamily H, member 5 Predicted membrane proteins Microtubules Tissue enhanced
KCNH7 Potassium channel, voltage gated eag related subfamily H, member 7 Predicted membrane proteins Tissue enriched
KCNIP3 Kv channel interacting protein 3, calsenilin Predicted intracellular proteins Vesicles Tissue enhanced
KCNIP4 Kv channel interacting protein 4 Predicted intracellular proteins Vesicles Tissue enhanced
KCNJ1 Potassium channel, inwardly rectifying subfamily J, member 1 Disease related genes Tissue enriched
KCNJ11 Potassium channel, inwardly rectifying subfamily J, member 11 Disease related genes Tissue enhanced
KCNJ12 Potassium channel, inwardly rectifying subfamily J, member 12 FDA approved drug targets Nucleoplasm Group enriched
KCNJ14 Potassium channel, inwardly rectifying subfamily J, member 14 Predicted membrane proteins Nucleoli Mixed
KCNJ15 Potassium channel, inwardly rectifying subfamily J, member 15 Predicted intracellular proteins Vesicles Tissue enhanced
KCNJ16 Potassium channel, inwardly rectifying subfamily J, member 16 Predicted intracellular proteins Vesicles Group enriched
KCNJ18 Potassium channel, inwardly rectifying subfamily J, member 18 Disease related genes Nucleoplasm Group enriched
KCNJ2 Potassium channel, inwardly rectifying subfamily J, member 2 Disease related genes Tissue enhanced
KCNJ3 Potassium channel, inwardly rectifying subfamily J, member 3 Plasma proteins Tissue enhanced
KCNJ5 Potassium channel, inwardly rectifying subfamily J, member 5 Cancer-related genes Tissue enhanced
KCNJ8 Potassium channel, inwardly rectifying subfamily J, member 8 Disease related genes Mixed
KCNJ9 Potassium channel, inwardly rectifying subfamily J, member 9 Predicted membrane proteins Tissue enriched
KCNK1 Potassium channel, two pore domain subfamily K, member 1 Predicted membrane proteins Vesicles Mixed
KCNK10 Potassium channel, two pore domain subfamily K, member 10 Predicted membrane proteins Tissue enhanced
KCNK13 Potassium channel, two pore domain subfamily K, member 13 Predicted membrane proteins Nuclear speckles Tissue enhanced
KCNK15 Potassium channel, two pore domain subfamily K, member 15 Predicted membrane proteins Tissue enhanced
KCNK17 Potassium channel, two pore domain subfamily K, member 17 Predicted membrane proteins Tissue enhanced
KCNK18 Potassium channel, two pore domain subfamily K, member 18 Disease related genes Not detected
KCNK2 Potassium channel, two pore domain subfamily K, member 2 FDA approved drug targets Mitochondria Tissue enhanced
KCNK5 Potassium channel, two pore domain subfamily K, member 5 Predicted membrane proteins Nucleus Tissue enhanced
KCNK6 Potassium channel, two pore domain subfamily K, member 6 Predicted membrane proteins Plasma membrane Mixed
KCNK7 Potassium channel, two pore domain subfamily K, member 7 Predicted intracellular proteins Plasma membrane Tissue enriched
KCNMA1 Potassium channel, calcium activated large conductance subfamily M alpha, member 1 Disease related genes Tissue enhanced
KCNMB2 Potassium channel subfamily M regulatory beta subunit 2 Predicted membrane proteins Tissue enhanced
KCNMB3 Potassium channel subfamily M regulatory beta subunit 3 Predicted intracellular proteins Nucleus Mixed
KCNMB4 Potassium channel subfamily M regulatory beta subunit 4 Predicted membrane proteins Cytosol Group enriched
KCNN1 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 1 Predicted intracellular proteins Actin filaments Tissue enriched
« prev | Page next »
